Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 12, 2013, Pages 1438-1446

  Chin, Melanie ^a   Ivy Lee, Chun Yue ^a   Chuang, Jen Chieh ^a   Bumeister, Ron ^a   Christian Wigley, W ^a   Sonis, Stephen T ^b   Ward, Keith W ^a   Meyer, Colin ^a  

^a Reata Pharmaceuticals Inc   (United States)

^b Biomodels   (United States)

Author keywords

Bardoxolone methyl; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ASPARTATE AMINOTRANSFERASE; BARDOXOLONE METHYL; BILIRUBIN; CREATININE; DH 404; GLUCOSE; INSULIN; RTA 405; TRIACYLGLYCEROL; TRITERPENOID; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FATTY LIVER; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; KIDNEY TUBULE; KIDNEY TUBULE BASEMENT MEMBRANE; LIPID DIET; LIPID STORAGE; LIVER CELL; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ZUCKER DIABETIC FATTY RAT;

EID: 84879175433     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00387.2012     Document Type: Article

References (30)

1. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKK-beta on Cys-179. J Biol Chem 281: 35764-35769, 2006.
2. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 335: 2-12, 2010.
3. Ballatori N, Truong AT. Glutathione as a primary osmotic driving force in hepatic bile formation. Am J Physiol Gastrointest Liver Physiol 263: G617-G624, 1992.
4. Charles River Rodent Production: North America [Online]. http://www. criver.com/HealthData/H03K9801.pdf [20 Apr. 2012].
5. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 102: 4584-4589, 2005.
6. Ichikawa T, Li J, Meyer CJ, Janicki JS, Hannink M, Cui T. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLos One 4: e8391, 2009.
7. Jaeschke H, Wendel A. Choleresis and increased biliary efflux of gluta-thione induced by phenolic antioxidants in rats. Toxicology 52: 225-235, 1988.
8. Li J, Stein TD, Johnson JA. Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. Physiol Genomics 18: 261-272, 2004.
9. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67: 2414-2419, 2007.
10. Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 168: 1960-1974, 2006.
11. Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, Kensler TW. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci 104: 218-227, 2008.
12. Reisman SA, Csanaky IL, Yeager RL, Klaassen CD. Nrf2 activation enhances biliary excretion of sulfobromophthalein by inducing glutathione-S-transferase activity. Toxicol Sci 109: 24-30, 2009.
13. Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L. The triterpenoid CDDO-Me has potent antidiabetic effects in diet-induced diabetic mice and Leprdb/db mice. J Biol Chem 285: 40581-40592, 2010.
14. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361, 2008.
15. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M, Kensler TW. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide. Eur J Pharmacol 620: 138-144, 2009.
16. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74: 537-545, 2011.
17. Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49: 147-158, 2010.
18. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 97: 4844-4849, 2000.
19. Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60: 625-633, 2011.
20. Tanaka Y, Aleksunes LM, Goedken MJ, Chen C, Reisman SA, Manautou JE, Klaassen CD. Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicol Appl Pharmacol 231: 364-373, 2008.
21. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL, Klaassen CD. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 325: 655-664, 2008.
22. Vora JP, Zimsen SM, Houghton DC, Anderson S. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 7: 113-117, 1996.
23. Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL. Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. Hepatology 50: 1588-1596, 2009.
24. Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, Ferguson DA, Grossman E, Chen J, Zhou XJ, Hartono J, Winterberg P, Chen B, Agarwal A, Lu CY. Bardoxolone Methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes: Nrf2, PPARgamma, and HO-1. Am J Physiol Renal Physiol 300: F1180-F1192, 2011.
25. Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes 61: 3208-3218, 2012.
26. Xu KZ, Zhu C, Kim MS, Yamahara J, Li Y. Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity. J Ethnopharmacol 123: 280-287, 2009.
27. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 6: 154-162, 2007.
28. Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, Morito N, Koyama A, Yamamoto M, Takahashi S. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 60: 1343-1353, 2001.
29. Zoja C, Corna D, Locatelli M, Corna C, Cattaneo S, Meyer C, Remuzzi G, Benigni A. Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria. Poster American Society of Nephrology Meeting, November, 2010.
30. Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effets. Am J Physiol Renal Physiol 304: F808-F819, 2013.